Wells Fargo raised the firm’s price target on Aflac (AFL) to $103 from $102 and keeps an Equal Weight rating on the shares. The firm notes Q1 came with weaker-than-expected sales in both Japan and the U.S. and a slip in the ESR. Sales continue to be weak, but management noted it expects the new cancer product to help boost JPY sales year-over-year and expects higher cancer sales in 2025 vs. 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFL:
- Aflac Reports Q1 Earnings Amid Investment Losses
- Aflac’s Earnings Call: Growth Amid Financial Pressures
- AFLAC’s Strong Japanese Market Performance and Operational Efficiency in the U.S. Justify Buy Rating Despite EPS Miss
- Aflac price target raised to $96 from $95 at Barclays
- Closing Bell Movers: Microsoft and Meta rally after earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue